Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli

Galibert, Francis; Mandart, Elisabeth; Fitoussi, Françoise; Tiollais, Pierre; Charnay, Patrick

doi:10.1038/281646a0

Cited by 943 publications

(561 citation statements)

References 31 publications

Supporting

Mentioning

546

Contrasting

Unclassified

Order By: Relevance

“…26 Because of the nature of the overlapping reading frames of the HBV genome, this region also corresponds to aa 40 up to the stop codon of HBsAg. 27 The nucleotide numbering starts with the EcoR1 site in the HBV genome (EcoR1 ϭ 1), and the sequences were compared with the appropriate wild-type sequence of ayw 27 or adw2. 28 …”

Section: Methodsmentioning

confidence: 99%

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation

Tillmann¹,

Trautwein²,

Bock³

et al. 1999

Hepatology

127

View full text Add to dashboard Cite

Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT).Eighteen of 20 patients with insufficient response to FCV were treated with 100 mg LAM daily after OLT. These patients had shown nonresponse (n ‫؍‬ 5), partial response (n ‫؍‬ 7), or breakthrough (n ‫؍‬ 6) during FCV therapy. Despite passive immunoprophylaxis with hepatitis B immunoglobulin after liver transplantation, HBV reinfection had occurred in 14 of 15 transplanted patients. HBV-DNA levels and the regions A to E of the HBV-DNA polymerase gene were analyzed before and after treatment failure to either therapy. Within 4 weeks on LAM, all but 1 patient showed a 95% average reduction of the HBV-DNA level. As with FCV, we did not observe any severe side-effects attributable to LAM. However, 7 patients developed a breakthrough within 12, 29 (n ‫؍‬ 2), 32, 37, 54, and 145 weeks under treatment with LAM associated with the methionine-to-valine signature mutation (M552V) in the YMDD motif in all. With FCV, no unique, but a dominant, resistance pattern with the L528M mutation was identified for patients with breakthrough under FCV. In contrast, nonresponders or patients with partial response to FCV did not exhibit such mutations. Our results indicate that the L528M mutation is a risk factor for LAM breakthrough, because breakthrough during LAM occurred earlier in patients with this mutation (50 ؎ 10 weeks vs. 120 ؎ 21 weeks). Because breakthrough on either treatment is frequent for this specific group of patients, the use of combination therapy should be explored. (HEPATOLOGY 1999;30:244-256.)Hepatitis B virus (HBV) infection affects more than 300 million people worldwide. The infection frequently leads to cirrhosis and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is a therapeutic option for end-stage liver disease. Results of liver transplantation for HBV-related end-stage liver disease are worse compared with other benign indications for liver transplantation, 1 because HBV reinfection often runs a severe course in liver graft recipients, 2,3 with an estimated 3-year survival of only 54%. 4 Treatment with passive immunoprophylaxis with hyperimmunoglobulin against hepatitis B surface antigen (HBIg) has improved the outcome of these patients. 5 In some patients, in particular if pretransplantation replication levels were high, this regime fails to prevent recurrence of HBV. Thus, additional treatment options are needed for these patients .6 Two new oral nucleoside analogues, lamivudine (LAM) and famciclovir (FCV), have been reported as potent inhibitors of hepadnaviral replication in vitro 7,8 and in vivo. 9-12 HBV replicates via an intermediate RNA step through the process of reverse transcription. As a consequence, the mutation rate in the HBV genome is increased compared with other DNA viruses as a result of the lack of proofreading activity in the viral polymerase. Nonresponse or resistance to nucleoside analogues can be rel...

show abstract

Section: Methodsmentioning

confidence: 99%

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation

Tillmann¹,

Trautwein²,

Bock³

et al. 1999

Hepatology

127

View full text Add to dashboard Cite

show abstract

“…Since the discovery of HBV variants, several studies has been carried out that focused on the viral factors affecting disease outcome. [4][5][6][7] On the other hand, some family studies have examined the role of host factors by characterizing the genetic basis for susceptibility to HBV infection. 8 In the last decade several studies have established the significance and influence of host genes on the outcome of viral hepatitis.…”

Section: W Orldwide Hepatitis B Virus (Hbv) Associatedmentioning

confidence: 99%

Association of Interleukin-1β and Gene Polymorphisms with Liver Pathogenesis in Hepatitis B Virus Infection among Eastern Indian Population

Biswas

Panigrahi

Pal

et al. 2013

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Background: Interleukin-1b (IL-1b) is an important member of the family of the proinflammatory cytokines that modulate outcome of hepatitis B virus (HBV) infection. Objectives: This study was designed to investigate the relationship between the polymorphic genotypes of the interleukin-1b (IL-1b) promoter region and the interleukin-1 receptor antagonist gene (IL-1RN) and disease outcome in HBV-infected individuals. Methods: DNA was extracted from 395 study subjects including HBV carriers with varying clinical presentations, as well as healthy controls and spontaneously recovered cases (SRC). Polymorphisms in IL-1b (at position À511) and IL-1RN (variable nucleotide tandem repeats, VNTR) were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and PCR based assay respectively. Results: Among the study subjects, different IL-1b (at position À511) (CC, CT and TT) and IL-1RN (1/1, 1/2, 2/2 and 1/3) polymorphic genotypes were found at variable proportions. Logistic regression analysis revealed, no notable difference at the level of IL-1b promoter (P = 0.244; OR = 0.78; 95% CI = 0.52-1.18) or IL-1RN genotype polymorphism (P = 0.840; OR = 1.03; 95% CI = 0.78-1.36) among the HBV carriers and controls or SRC cases. Pairwise proportion testing showed, IL-1b À511 genotype CC was significantly higher among asymptomatic carriers (ASC) in comparison with liver cirrhosis (LC) patients (P value = 0.028) and healthy control group (P-value = 0.036). IL-1RN genotype 2/2 was considerably higher in LC group than SRC as well as control group. Combinations of IL-1b (À511) and IL-1RN polymorphisms were associated with disease progression, such as CC-1/2 with ASC and TT-2/2 with LC. Conclusion: IL-1b polymorphisms are found to be associated with disease severity. Different polymorphic combinations are associated with degree of disease severity. Overall this is the first report from Eastern India, which shows association of IL-1b polymorphisms with HBV-related hepatic complications. ( J CLIN EXP HEPATOL 2013;3:281-287)

show abstract

“…Both genes were brought under the control of the SV40 early promoter/enhancer for comparing the reporter systems. In all promoter constructions the transcription start point (cap site) was cloned in original position to its promoter, whereas the trans- (Galibert et al, 1979). The ends of this 1855bp fragment were converted to BglII (5'-end) and Sal1 sites (3'-end), respectively, to generate pAvBI1, which was obtained from Albrecht von Brunn, ZMBH, Heidelberg.…”

Section: (A) Construction Of Reporter Plasmidsmentioning

confidence: 99%

Hepatitis B virus surface antigen as a reporter of promoter activity

Marschall

Motz

Leser

et al. 1989

Gene

View full text Add to dashboard Cite

SUMMARYThe coding sequence for the hepatitis B virus surface antigen (HBsAg) was used as a new reporter gene for studies on eukaryotic promoter activity and upstream regulatory sequences. The data observed in transfection assays were comparable to results obtained with conventional chloramphenicol acetyltransferase (CAT) assays, as was demonstrated using various transcriptional regulation sequences. The expression of HBsAg as a reporter protein offered some advantages:(i) In transient expression assays, a time course of promoter activity depending on variable culture conditions could be monitored over a period of time, since the HBsAg was secreted into the culture supematant.(ii) Evaluation of HBsAg from supematant aliquots and quantification of the corresponding promoter activities could be performed easily, using the very sensitive and readily available diagnostic HBsAg kits.(iii) In contrast to the conventional CAT assay, the cells remained available for further tests, e.g., Western blot, immunofluorescence or transcript analysis.Characteristics of several Epstein-Barr virus (EBV) promoters, depending on the virus state of EBV-positive B-cells (latency, chemical induction, lytic superinfection, truns-activation), were assayed using the HBsAg reporter system.

show abstract

Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli

Cited by 943 publications

References 31 publications

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation

Association of Interleukin-1β and Gene Polymorphisms with Liver Pathogenesis in Hepatitis B Virus Infection among Eastern Indian Population

Hepatitis B virus surface antigen as a reporter of promoter activity

Contact Info

Product

Resources

About